Skip to content
Trial Eligibility
Menu

BPL-1357 Against H1N1 Influenza Virus Challenge

NCT07215858

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Background: Influenza (flu) infections are a serious global health threat. Each year, between 3 and 5 million people get the flu, and up to 500,000 die from it. Current vaccines protect against seasonal flus, but broader vaccines are needed to protect against potential flu pandemics. Objective: To test an experimental flu vaccine. Eligibility: Healthy people aged 18 to 55 years. Design: The study will last 5 to 8 months and has 2 phases, A and B. The study vaccine will be given either as a shot in the arm or as a nasal spray.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Influenza
  • Human

Eligibility basics and study details

Study type
Interventional
Phase
Phase 2
Ages
18 to 55 years
Sex
All
Healthy volunteers
Accepted
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Last updated on ClinicalTrials.gov
October 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Maryland · 1

  • National Institutes of Health Clinical Center · Bethesda, MD

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.